



ten23 health® publishes 2023 Fairstainability Impact Report detailing major progress on its sustainability goals

Basel, 22nd April, 2024. ten23 health®, a leading Swiss contract development and manufacturing organization, today announced the release of its 2023 Fairstainability Impact Report which outlines major progress on its sustainability goals.

ten23 health® combines Sustainability and Fairness reporting into “Fairstainability”. As a Swiss-based organization, ten23 health® recognizes the importance of environmental stewardship and social responsibility – its mission is to drive positive change in the pharmaceutical and CDMO industry. The 2023 Fairstainability Impact Report transparently provides the current status of key parameters and progress towards achieving its sustainability goals.

“We are incredibly proud to announce significant progress on our sustainability agenda with the release of our third Fairstainability Report,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO) at ten23 health. *“Patients, People and Planet are our central commitments, and sustainability is at the core of everything we do.”*

Highlights of the 2023 Fairstainability Report include:

1. **Reduction in carbon footprint and net positive operations:** ten23 health® has reduced its carbon footprint intensity (scope 1 and 2 GHG emissions/revenue) by 44% since 2021 and is expecting to meet its 50% reduction target one year earlier than planned. Initiatives include energy-efficient manufacturing processes, reduction of energy consumption, use of renewable energy sources, and optimization of transportation logistics. 104% of unavoidable total operational GHG emissions were compensated, with Atmosfair, Generation Forest and direct carbon capture via Climeworks.
2. **Waste reduction efforts:** The company has diverted 43% of waste from disposal in 2023, up from 34% in 2022. Waste reduction strategies include recycling programs and waste minimization initiatives such as separation of waste and switching to reusable materials where possible. We also offset

150% of our plastic waste sent to incineration by our partnership with Seven Clean Seas, which removes plastics from the ocean.

3. **Fairness:** ten23 health® is committed to fairness and equality, we have 48% women employees and a certified “no gender pay gap”.
4. **Community engagement:** the company actively engages with local communities and their employees through various initiatives, including employee volunteer programs like Cleanup Day, internal sustainability workshops, personal footprint assessment, training and offsetting.
5. **Certifications & Awards:** in 2023, ten23 obtained the EcoVadis Silver medal as top 13% in our industry category, won 2nd place in the “Swiss HR award” and 3rd place of the “modern work award”. We were also awarded the Pride Champion Gold Award in 2023.

The release of 2023 Fairstainability Report underscores ten23 health’s dedication and commitment to transparency and accountability in its Fairness and Sustainability efforts. By continually assessing its environmental and social impact, the company strives to be a leader and disruptor in sustainable pharmaceutical manufacturing.

To access the full 2023 Fairstainability Report and learn more about ten23 health’s sustainability initiatives, visit the company’s website at [Patients, People, Planet | ten23 health](#)

About ten23 health®

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company’s name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022×10^{23} . Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to

understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m – €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 79 489 39 05

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021